ARYx Therapeutics, Inc. (ARYX) Research

Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.

Market snapshot

Symbol
ARYX
Price
$0.00
Day change
0.00%
Market cap
$16.7K
P/E ratio
-0.00x
52-week range
0.000001-0.0005
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Abattis Bioceuticals Corp. (ATTBF)
  • Nutranomics, Inc. (NNRX)
  • Naturally Splendid Enterprises Ltd. (NSPDF)
  • Nunzia Pharmaceutical Company (NUNZ)
  • Onassis Holdings Corp. (ONSS)
  • OWC Pharmaceutical Research Corp. (OWCP)
  • Virtual Medical International, Inc. (QEBR)
  • Response Genetics, Inc (RGDXQ)

Recent insider activity

  • Growth Equity Opportunities Fund, LLC — S-Sale (4469274 shares) on 2011-03-10
  • DRANT RYAN D — S-Sale (4469274 shares) on 2011-03-10
  • KOLLURI KRISHNA KITTU — S-Sale (4469274 shares) on 2011-03-10
  • KERINS PATRICK J — S-Sale (4469274 shares) on 2011-03-10
  • SIMON NICHOLAS J III — P-Purchase (500000 shares) on 2010-09-30

Open ARYx Therapeutics, Inc. (ARYX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.